Thomas Joseph Weber, MD

Professor of Medicine
Member of the Duke Cancer Institute
Campus mail 303 Baker House, Durham, NC 27710
Phone (919) 668-1364
Email address thomas.weber2@duke.edu

Osteoporosis, with current studies that focus on advances in diagnosis and natural history of male and postmenopausal osteoporosis. The study on male osteoporosis include a collaborative study with outside investigators is examining the utility of lateral spine bone densitometry in identifying men with osteoporosis and low trauma fractures.

Hypophosphatemic disorders, including X-link hypophosphatemic rickets and tumor-induced osteomalacia. My ongoing research study, in collaboration with Dr. L Darryl Quarles at the University of Kansas, seeks to further confirm and extend our understanding of the role of FGF-23 in human disorders of phosphate homeostasis, including patients with chronic kidney disease. Pending studies include primary and sub-investigator directed Phase 1 / 2 first in human studies examining the effects of a monoclonal antibody and enzyme replacement therapy for X-linked hypophosphatemic rickets and hypophosphatasia, respectively.

Education and Training

  • Fellow in Endocrinology, Medicine, Duke University, 1993 - 1997
  • Instructor, Medicine, Yale University, 1992 - 1993
  • Medical Resident, Medicine, Yale University, 1989 - 1992
  • M.D., The University of Chicago, 1989

Publications

Jan de Beur, Suzanne M., Paul D. Miller, Thomas J. Weber, Munro Peacock, Karl Insogna, Rajiv Kumar, Frank Rauch, et al. “Reply to: Burosumab for Tumor-Induced Osteomalacia: not Enough of a Good Thing.” J Bone Miner Res 36, no. 12 (December 2021): 2455–56. https://doi.org/10.1002/jbmr.4317.

PMID
34030212
Full Text

Dahir, K., M. B. Zanchetta, I. Stanciu, C. Robinson, J. Y. Lee, R. Dhaliwal, J. Charles, et al. “Diagnosis and Management of Tumor-induced Osteomalacia: Perspectives from Clinical Experience.” Journal of the Endocrine Society 5, no. 9 (September 1, 2021). https://doi.org/10.1210/jendso/bvab099.

Full Text

Briot, Karine, Anthony A. Portale, Maria Luisa Brandi, Thomas O. Carpenter, Hae Ii Cheong, Martine Cohen-Solal, Rachel K. Crowley, et al. “Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension.” Rmd Open 7, no. 3 (September 2021). https://doi.org/10.1136/rmdopen-2021-001714.

PMID
34548383
Full Text

Jan de Beur, Suzanne M., Paul D. Miller, Thomas J. Weber, Munro Peacock, Karl Insogna, Rajiv Kumar, Frank Rauch, et al. “Burosumab for the Treatment of Tumor-Induced Osteomalacia.” J Bone Miner Res 36, no. 4 (April 2021): 627–35. https://doi.org/10.1002/jbmr.4233.

PMID
33338281
Full Text

Portale, Anthony A., Thomas O. Carpenter, Maria Luisa Brandi, Karine Briot, Hae Ii Cheong, Martine Cohen-Solal, Rachel Crowley, et al. “Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period.” Calcif Tissue Int 105, no. 3 (September 2019): 271–84. https://doi.org/10.1007/s00223-019-00568-3.

PMID
31165191
Full Text

Kim-Chang, Julie J., Lorena Wilson, Cliburn Chan, Bernard Fischer, Guglielmo Venturi, Maureen M. Goodenow, Grace Aldrovandi, Thomas J. Weber, John W. Sleasman, and John W. Adolescent Medicine Trials Network for HIV/AIDS Interventions. “Tenofovir Has Minimal Effect on Biomarkers of Bone Health in Youth with HIV Receiving Initial Antiretroviral Therapy.” Aids Res Hum Retroviruses 35, no. 8 (August 2019): 746–54. https://doi.org/10.1089/AID.2018.0270.

PMID
31115244
Full Text

De Beur, Suzanne Jan, Paul D. Miller, Thomas J. Weber, Munro Peacock, Karl L. Insogna, Rajiv Kumar, Frank Rauch, et al. “Burosumab Improved Serum Phosphorus, Osteomalacia, Mobility, and Fatigue in the 48-Week, Phase 2 Study in Adults with Tumor-induced Osteomalacia Syndrome.” In Journal of Bone and Mineral Research, 33:50–50. WILEY, 2018.

Scholars@Duke

Insogna, Karl L., Karine Briot, Erik A. Imel, Peter Kamenický, Mary D. Ruppe, Anthony A. Portale, Thomas Weber, et al. “A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.” J Bone Miner Res 33, no. 8 (August 2018): 1383–93. https://doi.org/10.1002/jbmr.3475.

PMID
29947083
Full Text

De Beur, Suzanne Jan, Paul D. Miller, Thomas J. Weber, Munro Peacock, Mary D. Ruppe, Karl Insogna, Diana Luca, Christina Theodore-Oklota, Javier San Martin, and Thomas Carpenter. “Effects of Burosumab (KRN23), a Human Monoclonal Antibody to FGF23, in Patients with Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS).” In Journal of Bone and Mineral Research, 32:S280–S280. WILEY, 2017.

Scholars@Duke

Weber, Thomas J., James Koh, Samantha M. Thomas, Joyce A. Hogue, Randall P. Scheri, Sanziana A. Roman, and Julie A. Sosa. “Impaired calcium sensing distinguishes primary hyperparathyroidism (PHPT) patients with low bone mineral density.” Metabolism 74 (September 2017): 22–31. https://doi.org/10.1016/j.metabol.2017.06.004.

PMID
28764845
Full Text

Pages